Abstract. Insulinoma is the most common cause of fasting hypoglycemia resulting from autonomous insulin hypersecretion. A 59-year-old woman who had previously had an insulinoma and had undergone a partial pancreatectomy was admitted to our hospital because of recurrence of hypoglycemia after 27 years. She had two unusual endocrinological features: 1) the serum insulin response to intravenous secretin injection was not impaired, and 2) the serum C-peptide levels and ratios of serum C-peptide to insulin were relatively low. Two pancreatic tumors were readily detectable by computed tomography (CT) and magnetic resonance imaging (MRI). The selective arterial calcium injection (SACI) test showed a hyperinsulinemic response by calcium administration to the gastroduodenal artery. A partial pancreatectomy was done and her hypoglycemia disappeared. Histology revealed that the tumors were composed of monotonous, small round cells that were positive for both insulin and cathepsin B. As previous in vitro studies have shown that C-peptide can be metabolized within human insulinoma cells by proteolytic cleavage by cathepsin B, our patient's low serum C-peptide levels might have been caused by degradation of C-peptide by cathepsin B. According to the data from the literature, the molar ratio of serum C-peptide to insulin is generally decreased in patients with insulinoma than normal subjects. This case highlights the need for careful interpretation of C-peptide levels and the intravenous secretin injection test in the diagnosis of insulinoma.
INSULINOMA is a tumor of the insulin-producing β cells of the pancreatic islets, and often causes severe and disabling hypoglycemia. The incidence of insulinoma is very low; four cases per one million personyears [1] . Diagnosis of insulinoma requires confirmation of hypoglycemia, evidence of inappropriate insulin secretion, and identification of a pancreatic mass by medical imaging or angiography [2] [3] [4] [5] . The intravenous secretin injection test is useful for the diagnosis of insulinoma because of its high specificity (100%) and high sensitivity (75%) [6] [7] [8] . The use of C-peptide levels to assess of endogenous insulin secretion is also considered reliable for the diagnosis of insulinoma [9] [10] [11] [12] [13] . This report describes a patient with insulinoma who had two endocrinological features: 1) the serum insulin response to intravenous secretin injection was not impaired, and 2) the serum C-peptide levels and ratios of serum C-peptide to insulin were relatively low.
Methods

Laboratory methods
Except when otherwise stated, serum insulin and C-peptide levels were measured using the following assays.
Serum insulin levels were determined using a twosite immunoenzymometric assay (ST AIA-PACK IRI; AIA-1800 System; TOSOH, Yamaguchi, Japan). The sensitivity was 1.5 µU/mL, and the intra-and interassay coefficients of variation were <3% and <5%, respectively. The reference range of fasting serum insulin concentration was 1.1-17.0 µU/mL, as determined in serum samples of 200 healthy individuals. The cross-reactivity with proinsulin is less than 2%. To convert µU/mL into pmol/L, multiply by 6.092.
Intact-proinsulin levels were determined by means of a specific chemiluminescence test (MLT Intact Proinsulin; Molecular Light Technology, Cardiff, Wales, UK). The intra-and inter-assay coefficients of variation were 5.2% and 8.6%, respectively. The reference range of fasting serum intact-proinsulin was 1.4-6.0 pmol/L. Serum C-peptide levels were determined using a two-site immunoenzymometric assay (ST AIA-PACK C-Peptide; AIA-1800 System; TOSOH, Yamaguchi, Japan). The minimal detectable concentration of Cpeptide was 0.2 ng/mL and the intra-and inter-assay coefficients of variation were <3% and <6%, respectively. The reference range of fasting serum C-peptide concentration was 1.1-3.3 ng/mL, determined in serum samples of 103 healthy individuals. The cross-reactivities of the assay with proinsulin and insulin are 69% and 0.005%, respectively. To convert ng/mL into pmol/L, multiply by 331.
We performed MEN1 gene analysis after obtaining written informed consent from the patient. Genomic DNA was isolated from peripheral mononuclear cells and mutational analysis of the gene was done by complete sequence analysis of the nine coding exons and corresponding exon/intron boundaries.
Immunohistochemistry
The resected surgical specimen was fixed in 10% formalin and paraffin sections were cut at 4 µm thickness and mounted on glass slides. Slides were dewaxed and rehydrated. For detection of cathepsin B, the mounted sections were subjected to antigen retrieval by autoclaving at 121°C for 5 min with 10 mM citrate buffer. Endogenous peroxidase was inactivated with 0.3% H 2 O 2 in methanol for 30 min. The slides were blocked for 1 h at room temperature with a reagent containing casein (DAKO Protein Block SerumFree Solution; Dako, Glostrup, Denmark), then stained overnight at 4°C with guinea pig anti-swine insulin antibody, 1:500 dilution (Dako) and mouse anti-human cathepsin B antibody, 1:50 dilution (Serotec, Oxford, UK). The slides were washed with phosphate buffered saline on the following day and incubated for 2 h at room temperature with biotinylated goat anti-guinea pig IgG antibody (1:200 dilution) and biotinylated horse anti-mouse IgG antibody (1:200 dilution) as secondary antibodies (both from Vector, Burlingame, CA, USA). The slides were then incubated with an avidinbiotin complex (ABC) reagent (Vectastain Elite ABC Kit; Vector) for 50 min at room temperature followed by addition of diaminobenzidine tetrahydrochloride (DAB) (Dako) as the substrate-chromogen solution. After hematoxylin counterstaining and dehydration, slides were mounted in mounting medium (MGK-S; Matsunami, Osaka, Japan) and pictures were taken using an Axioskop Microscope (Carl Zeiss, Oberkochen, Germany).
Case Report
A 59-year-old woman was admitted to our hospitals for detailed examination of hypoglycemia. She had been previously diagnosed with insulinoma 27 years earlier and underwent a body-tail pancreatectomy to remove the tumor. Thereafter, annual medical checkups were carried out and she remained well and asymptomatic. However, in the year in which she was referred to our hospitals, she was found to have fasting hypoglycemia (30 mg/dL). On admission, she was 151.3 cm tall, weighed 51.5 kg (body mass index, 22.5 kg/m 2 ) and had a blood pressure of 138/96 mmHg.
Laboratory and endocrinological data are summarized in Table 1 . No abnormalities in blood count, urinalysis, or liver and renal functions were found on admission. Evaluation of pancreatic endocrine function showed a relatively high serum insulin level (10.7 µU/mL), a significantly high serum proinsulin level (28.4 pmol/L), a low serum C-peptide level (0.40 ng/ mL), and a low fasting plasma glucose level of 39 mg/ dL. Her hemoglobin A1c level was at the lower end of the normal range (4.3%). Adrenal insufficiency, hypopituitarism, and insulin autoimmune syndrome were excluded as causes of her hypoglycemia on the basis of laboratory and endocrine data. Her mother had dia- betes, but otherwise there was no family history of endocrinopathy or endocrine neoplasia. There was no clinical or mutational evidence of multiple endocrine neoplasia type 1 (MEN1). Abdominal dynamic computed tomography (CT) showed enhancement of two well-circumscribed round tumors in the arterial phase (Figs. 1A-1C ). These masses appeared as high intensity areas in T2-weighted magnetic resonance images (MRI) (Fig. 1D) . Selective angiography was then performed. The arterial phase of the gastroduodenal artery angiogram showed the presence of two well-circumscribed hypervascular tumors in the pancreas (Fig. 2A) . We performed the selective arterial calcium injection (SACI) test to make a functional diagnosis of the tumors [14] . Boluses of calcium gluconate (0.025 mEq/kg body mass) were injected into the gastroduodenal artery (GDA), superior mesenteric artery (SMA), and proper hepatic artery (PHA). Blood samples for measurement of insulin levels were taken from the right hepatic vein prior to the injection and at 30, 60, and 180 s after the injection. A significant increase in the level of insulin was observed in the GDA, but not in the SMA or PHA (Fig. 2B) .
Partial pancreatectomy was performed. Intraoperative ultrasonography revealed two tumors with hypoechoic lesions in the pancreas (Fig. 3A) . The tumors were surgically resected. The specimen contained two separate tumors, 2.0 × 1.5 × 1.5 cm and 1.3 × 1.0 × 1.0 cm in size (Fig. 3B) . The tumors were round encapsulated masses and their cut surface appeared solid and homogenous. Plasma glucose levels recovered to normal levels and hypoglycemia did not recur after the operation.
The imaging characteristics and the enhanced calcium sensitivity of this patient's tumors were typical of insulinoma [5] . In contrast, some of her endocrinological features appeared unique. We performed glucose tolerance tests and intravenous secretin injection tests before and after surgery (Figs. 4 and 5) . Before surgery, a 75 g oral glucose tolerance test (OGTT) resulted in an exaggerated insulin response (358 µU/mL) at 30 min (Fig. 4A) ; a 25 g intravenous glucose tolerance test (ivGTT) caused an even more exaggerated insulin response (455 µU/mL) at 15 min, which was followed by a decrease in plasma glucose level to 39 mg/dL at 30 min and neuroglycopenic symptoms (Fig. 4B) . The secretin test involved intravenous injection of 2 U/kg body mass of secretin followed by peripheral venous sampling at 2, 4, 6, 8, and 10 min post-injection for measurement of insulin concentrations. Secretin injection induced a fourfold increase in serum insulin level (Fig. 4C) , which is inconsistent with the typical response of an insulinoma. After surgery, the 75 g OGTT, 25 g ivGTT, and the secretin test were repeated at the 17th, 23rd, and 22nd postoperative days (Figs. 5A-5C). The insulin responses during the OGTT and the ivGTT were attenuated and plasma glucose levels were not hypoglycemic (Figs. 5A and 5B). Postopera- tive intravenous injection of secretin resulted in a prompt 15-fold increase in serum insulin level (Fig.  5C ). The peak insulin response was earlier (2 to 6 min) and lower (29.2 to 57 µU/mL) in the postoperative test compared with the preoperative test. The patient's serum C-peptide levels were sometimes less than the lower limit of fasting reference range (Figs. 4 and 6; 1.1-3 .3 ng/mL; cf. Methods). The postoperative ratios of serum C-peptide to insulin were significantly higher compared with the preoperative ratios (Fig. 6) . Similar results were obtained when insulin and C-peptide levels were measured using other methods (Insulin RIA bead; Abbott, Tokyo, Japan; Cpeptide RIA, Shionogi, Osaka, Japan). The dissociation between levels of C-peptide and insulin was particularly evident when serum insulin levels were high (Fig. 4) , and disappeared after surgery (Figs. 5 and 6 ). Histopathological examination was done with hematoxylin and eosin staining and with immunohistochemical staining (Fig. 7) . The microscopic characteristics of the two tumor specimens were similar; diffuse sheets of monotonous, small round cells and many blood-filled vascular cavities (Fig. 7A) . These findings were consistent with the diagnosis of insulinoma. An in vitro study showed that C-peptide, but not insulin, can be selectively metabolized within human insulinoma cells by proteolytic cleavage by cathepsin B [15] . Therefore, we stained serial tissue sections for insulin and cathepsin B (Figs. 7B and 7C ). The non-neoplastic islets (arrowheads) were strongly positive for insulin but negative for cathepsin B, whereas insulinoma cells were moderately positive for both insulin and cathepsin B.
Discussion
Our patient showed a positive insulin response to intravenous secretin injection before surgery as well as after surgery. In the presence of secretin, normal β cells release insulin, but insulinoma cells do not [6] . Although the reason for the unresponsiveness of insulinoma cells to secretin is not fully understood, it may be associated with impaired signal transduction via secretin receptor. The function of normal β cells in a pancreas with an insulinoma is suppressed by the autonomous hypersecretion of insulin by the insulinoma [16] . Therefore, the serum insulin response to intra- venous secretin injection reflects both the decreased secretory activities of insulinoma cells and the suppressed secretory activities of residual β cells. The sensitivity and specificity of this test for the diagnosis of insulinoma is 75% and 100%, respectively [7, 8] . Glaser et al. described two patients with insulinomas whose clinical features were very similar to those of our patient [17] . Both of Glaser's patients had multiple insulinomas without MEN1 and exhibited markedly enhanced insulin responses to glucose stimulation and positive insulin responses to secretin stimulation. Responsiveness to secretin and glucose in insulinoma patients might be associated with tumor multiplicity and recurrence. Further studies with greater numbers of patients are needed to assess the value of the secretin test for diagnosis of insulinoma. In our patient, preoperative serum C-peptide levels were sometimes below a normal level. Moreover, the levels were lower before the operation than after the operation but preoperative serum insulin levels were much higher than postoperative serum insulin levels. This indicates that the low preoperative C-peptide levels were caused by the insulinomas. Insulin and Cpeptide are produced in equimolar amounts during the conversion of proinsulin to insulin in pancreatic β cells and are then secreted into the portal vein. In contrast to insulin, C-peptide is not extracted by the liver, but enters the systemic circulation [10] . Furthermore, the concentration of C-peptide is not affected by insulin antibodies and exogenous insulin does not contain Cpeptide. Thus, serum C-peptide levels reflect endogenous insulin secretion more precisely than serum insulin levels, making serum C-peptide a more valid marker of excess insulin secretion in cases of insulinoma [13] . C-peptide measurements are also especially important for interpreting the results of the Cpeptide suppression test and the prolonged fasting test [11, 12] . Service et al. reported that insulinoma patients had C-peptide values at the end of the 72 h fasts greater than or equal to 0.20 nmol/mL (0.60 ng/mL); however, our case does not fulfill that criterion even before conducting the prolonged fasting test [12] . According to the data from the literature, the molar ratio of serum C-peptide to insulin is, in general, decreased in patients with insulinoma than normal subjects, while in our case the ratios were much lower (Table 2 ) [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
It was reported that gel filtration chromatography of C-peptide extracted from the tumors reveals lower molecular weight fragments in addition to the authentic C-peptide [32] . This suggests that, though our case is rare in that the serum C-peptide levels were extremely low, the C-peptide levels in general might lead clinicians to underestimate autonomous hypersecretion of insulin in insulinoma patients. A loss of C-peptide by progressive, extensive intracellular degradation has been detected in rat and human insulinoma cells [15, 33] . Cathepsin B is a cysteine proteinase that plays a major role in intracellular protein degradation in many tissues, and has been shown to be present in the secretory granules of human insulinoma cells [34] [35] [36] . Moreover, an in vitro study showed that C-peptide, but not insulin, is proteolytically cleaved by cathepsin B in the C-terminal region of the peptide, which is the region that one of the antibodies used in our assay recognizes [15] . We observed positive immunoreactivity for cathepsin B in the insulinoma cells but not in the normal islets. This suggests that the patient's low serum C-peptide levels could have been a result of enhanced degradation of C-peptide by cathepsin B in her insulinoma. It should be noted that C-peptide levels do not necessarily reflect actual insulin secretion in insulinoma.
In conclusion, this case report emphasizes some unusual features of an insulinoma, including a positive [18] 14.7 8 Kajinuma et al. [19] 12.1 20 Okada et al. [20] 11.2 136 Our case (after surgery) 17.6 1 Insulinoma Smythe et al. [21] 20.0 1 Katabami et al. [22] 7.2 4 Gin et al. [23] 6.3 8 Sakai et al. [18] 6.1 1 Scarlett et al. [24] 5.9 1 Saudek [25] 5.6 1 Gerbitz and Spelsberg [26] 5.0 5 Lebowitz and Blumenthal [27] 4.9 3 Kondo et al. [28] 4.2 3 Service [29] 3.6 1 Ciavarella et al. [30] 2.9 1 Turner and Heding [31] 2.0 2 Our case (before surgery) 2.0 1 insulin response to secretin and decreased C-peptide levels, of which clinicians should be aware. The diagnosis of insulinoma should not depend on some particular endocrinological tests and should be made comprehensively.
